Exacerbated transplant arteriosclerosis in inducible nitric oxide- deficient mice

Circulation

Volumn 97, Issue 20, 1998, Pages 2059-2065

  Koglin, Jörg ^a   Glysing Jensen, Troels ^a   Mudgett, John S ^d   Russell, Mary E ^a,b,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Immunology; Lymphocytes; Muscle, smooth; Remodeling; Transplantation

Indexed keywords

NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOSCLEROSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; HEART GRAFT; IMMUNE RESPONSE; IMMUNOHISTOLOGY; IMMUNOREGULATION; LYMPHOCYTE DIFFERENTIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER;

EID: 0032568475     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.20.2059     Document Type: Article

References (42)

1. Hosenpud JD, Novick RJ, Bennett LE, Keck BM, Fiol B, Daily OP. The Registry of the International Society for Heart and Lung Transplantation: thirteenth official report-1996. J Heart Lung Transplant. 1996;15:655-674.
2. Colvin RB, Chase CM, Winn HJ, Russell PS. Chronic allograft arteriopathy: insights from experimental models. In: Orosz CG, Sedmak DD, Ferguson RM, ed. Transplant Vascular Sclerosis. Austin, Tex: RG Landes; 1995:7-34.
3. Adams DH, Wyner LR, Karnovsky MJ. Experimental graft arteriosclerosis, II: immunocytochemical analysis of lesion development. Transplantation. 1993;56:794-799.
4. Russell ME, Wallace AF, Wyner LR, Newell JB, Karnovsky MJ. Upregulation and modulation of inducible nitric oxide synthase in rat cardiac allografts with chronic rejection and transplant arteriosclerosis. Circulation. 1995;92:457-464.
5. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 1992;6:3051-3064.
6. Lowenstein CJ, Snyder SH. Nitric oxide, a novel biologic messenger. Cell. 1992;70:705-707.
7. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis. 1995;38:87-104.
8. Liew FY. Regulation of lymphocyte functions by nitric oxide. Curr Opin Immunol. 1995;7:396-399.
9. Langrehr JM, Hoffman RA, Lancaster JR Jr, Simmons RL. Nitric oxide: a new endogenous immunomodulator. Transplantation. 1993;55:1205-1212.
10. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996;17:138-146.
11. Taylor-Robinson AW, Liew FY, Severn A, Xu D, McSorley SJ, Garside P, Padron J, Phillips RS. Regulation of the immune response by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells. Eur J Immunol. 1994;24:980-984.
12. Wei XQ, Charles IG, Smith A, Ure J, Feng GJ, Huang FP, Xu D, Muller W, Moncada S, Liew FY. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature. 1995;375:408-411.
13. Sarkar R, Meinberg EG, Stanley JC, Gordon D, Webb RC. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res. 1996;78:225-230.
14. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83:1774-1777.
15. Comwell TL, Arnold E, Boerth NJ, Lincoln TM. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol. 1994;267:C1405-C1413.
16. Groves PH, Banning AP, Penny WJ, Newby AC, Cheadle HA, Lewis MJ. The effects of exogenous nitric oxide on smooth muscle cell proliferation following porcine carotid angioplasty. Cardiovasc Res. 1995;30:87-96.
17. Seki J, Nishio M, Kato Y, Motoyama Y, Yoshida K. FK409, a new nitric-oxide donor, suppresses smooth muscle proliferation in the rat model of balloon angioplasty. Atherosclerosis. 1995;117:97-106.
18. McNamara DB, Bedi B, Aurora H, Tena L, Ignarro LJ, Kadowitz PJ, Akers DL. L-Arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem Biophys Res Commun. 1993;193:291-296.
19. Marks DS, Vita JA, Folts JD, Keaney JF Jr, Welch GN, Loscalzo J. Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Invest. 1995;96:2630-2638.
20. Yang X, Chowdhury N, Cai B, Brett J, Marboe C, Sciacca RR, Michler RE, Cannon PJ. Induction of myocardial nitric oxide synthase by cardiac allograft rejection. J Clin Invest. 1994;94:714-721.
21. Worrall NK, Lazenby WD, Misko TP, Lin TS, Rodi CP, Manning PT, Tillon RG, Williamson JR, Ferguson TB Jr. Modulation of in vivo alloreactivity by inhibition of inducible nitric oxide synthase. J Exp Med. 1995;181:63-70.
22. Akyurek LM, Fellstrom BC, Van ZQ, Hansson GK, Funa K, Larsson E. Inducible and endothelial nitric oxide synthase expression during development of transplant arteriosclerosis in rat aortic grafts. Am J Pathol. 1996;149:1981-1990.
23. Cai B, Roy DK, Sciacca R, Michler RE, Cannon PJ. Effects of immunosuppressive therapy on expression of inducible nitric oxide synthase (iNOS) during cardiac allograft rejection. Int J Cardiol. 1995;50:243-251.
24. Russell ME, Hancock WW, Akalin E, Wallace AF, Glysing-Jensen T, Willen TA, Sayegh MH. Chronic cardiac rejection in the LEW to F344 rat model: blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest. 1996;97:833-838.
25. Räisänen-Sokolowski A, Glysing-Jensen T, Mottram PL, Russell ME. Sustained anti-CD4/CD8 blocks inflammatory activation and intimal thickening in mouse heart allografts. Arterioscler Thromb Vasc Biol. 1997;17:2115-2122.
26. MacMicking JD, Nathan C, Hom G, Chartrain N, Fletcher DS, Trumbauer M, Stevens K, Xie QW, Sokol K, Hutchinson N, Chen H, Mudgett JS. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase [published erratum appears in Cell. 1995;81: following 1170]. Cell. 1995;81:641-650.
27. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice: the role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation. 1973;16:343-350.
28. Räisänen-Sokolowski A, Glysing-Jensen T, Koglin J, Russell ME. Reduced transplant arteriosclerosis in murine cardiac allografts placed in interferon-gamma knockout recipients. Am J Pathol. 1998;152:359-365.
29. Armstrong AT, Strauch AR, Kardan A, Starling RC. Morphometric and immunocytochemical analysis of coronary arterioles in human transplanted hearts. J Heart Lung Transplant. 1996;15:818-826.
30. Schwartz SM, deBlois D, O'Brien ER. The intima: soil for atherosclerosis and restenosis. Circ Res. 1995;77:445-465.
31. Geng YJ, Wu Q, Muszynski M, Hansson GK, Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. Arterioscler Thromb Vasc Biol. 1996;16:19-27.
32. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383:787-793.
33. Liew FY, Li Y, Severn A, Millott S, Schmidt J, Salter M, Moncada S. A possible novel pathway of regulation by murine T helper type-2 (Th2) cells of a Th1 cell activity via the modulation of the induction of nitric oxide synthase on macrophages. Eur J Immunol. 1991;21:2489-2494.
34. Taub DD, Cox GW. Murine Th1 and Th2 cell clones differentially regulate macrophage nitric oxide production. J Leukoc Biol. 1995;58:80-89.
35. Taylor-Robinson AW, Phillips RS, Severn A, Moncada S, Liew FY. The role of TH1 and TH2 cells in a rodent malaria infection. Science. 1993; 260:1931-1934.
36. von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA. 1995;92:1137-1141.
37. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest. 1992;90:1168-1172.
38. Böger RH, Bode-Böger SM, Brandes RP, Phivthong-ngam L, Böhme M, Nafe R, Mügge A, Fröhlich JC. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation. 1997;96:1282-1290.
39. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A. 1991;88:4651-4655.
40. Albina JE, Cui S, Mateo RB, Reichner JS. Nitric oxide-mediated apoptosis in murine peritoneal macrophages. J Immunol. 1993;150:5080-5085.
41. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3′, 5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood. 1981;57:946-955.
42. Garg UC, Hassid A. Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALB/C 3T3 fibroblasts by a cyclic GMP-independent mechanism. Biochem Biophys Res Commun. 1990;171:474-479.